GPX2 and prostate carcinoma: hsa-miR-17-3p was reported to act as a tumor suppressor both in vitro and in vivo for prostatic cancer and it has been demonstrated that this ability is due to the suppression of three critical primary mitochondrial antioxidant enzymes: manganese superoxide dismutase (MnSOD), glutathione peroxidase-2 (GPX-2) and thioredoxin reductase (TrxR2) (28,29).